LY3962681 vs UB-312

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: alpha-synuclein · full Parkinson's Disease pipeline

LY3962681

Developed by Eli Lilly and partners

Phase 1 in Parkinson's Diseaseoligonucleotide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2030 · NCT06565195 (registry estimate)

No aligned efficacy figure on record for this race.

UB-312

Developed by Vaxxinity

Phase 1 in Parkinson's Diseasevaccine
Partial signal

NCT04075318 · Phase 1 · completed

A randomized, quadruple-blind, placebo-controlled phase 1 study of the UB-312 vaccine in 70 participants. The design is sound but small, and its primary measures were safety and immunogenicity: anti-alpha-synuclein antibody responses were reported in blood while cerebrospinal-fluid responses were only partial, with no statistical analyses posted, so the primary outcomes read as mixed.

Reported efficacy

Frequency of Adverse Events (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in Blood (44 weeks); Immunogenicity of UB-312 as Determined by Anti-aSyn Antibodies in CSF (44 weeks): Frequency of Adverse Events (44 weeks): Part A: UB-312 40 mcg 22 TEAEs | Part A: UB-312 100 mcg 31 TEAEs | Part A: UB-312 40/300 mcg 25 TEAEs | Part A: UB-312 300 mcg 31 TEAEs | Part A: UB-312 40/1000 mcg 24 TEAEs | Part A: UB-312 1000 mcg 17 TEAEs | Part A: UB-312 2000 mcg 18 TEAEs | Part A: Placebo 25 TEAEs | Part B: UB-312 300/100 mcg 59 TEAEs | Part B: UB-312 300 mcg 42 TEAEs | Part B: Placebo 20 TEAEs (mixed)

Result source: NCT04075318

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLY3962681UB-312
OFF time, change—Not reported—Not reported
ON time without troublesome dyskinesia, change—Not reported—Not reported
UPDRS Part III, change—Not reported—Not reported
MDS-UPDRS Part II, change—Not reported—Not reported

OFF time, change

LY3962681
—Not reported
UB-312
—Not reported

ON time without troublesome dyskinesia, change

LY3962681
—Not reported
UB-312
—Not reported

UPDRS Part III, change

LY3962681
—Not reported
UB-312
—Not reported

MDS-UPDRS Part II, change

LY3962681
—Not reported
UB-312
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

LY3962681: no structured comparison results are available for Parkinson's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. LY3962681: 0 of 4 rows · UB-312: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUB-312
Dropout rate
100%2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
100%1000 mcg
NCT04075318 · Phase 1 · monotherapy
100%40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
16.7%40/300 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
14.3%300/100 mcg
NCT04075318 · Phase 1 · monotherapy
0%100 mcg
NCT04075318 · Phase 1 · monotherapy
0%40 mcg
NCT04075318 · Phase 1 · monotherapy
Discontinued due to AEs
—2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
—1000 mcg
NCT04075318 · Phase 1 · monotherapy
—40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
—300 mcg
NCT04075318 · Phase 1 · monotherapy
—40/300 mcg
NCT04075318 · Phase 1 · monotherapy
—300 mcg
NCT04075318 · Phase 1 · monotherapy
—300/100 mcg
NCT04075318 · Phase 1 · monotherapy
—100 mcg
NCT04075318 · Phase 1 · monotherapy
—40 mcg
NCT04075318 · Phase 1 · monotherapy
Serious AEs
0%2000 mcga
NCT04075318 · Phase 1 · monotherapy
show 8 more results
0%1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%40/1000 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
0%40/300 mcg
NCT04075318 · Phase 1 · monotherapy
0%300 mcg
NCT04075318 · Phase 1 · monotherapy
42.9%300/100 mcg
NCT04075318 · Phase 1 · monotherapy
0%100 mcg
NCT04075318 · Phase 1 · monotherapy
0%40 mcg
NCT04075318 · Phase 1 · monotherapy
Most frequent reported AEs
2000 mcga
general disorders and administration site conditions 83.3% (placebo 62.5%)
nervous system disorders 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
show 8 more results
1000 mcg
general disorders and administration site conditions 100% (placebo 62.5%)
infections and infestations 33.3% (placebo 62.5%)
nervous system disorders 33.3% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40/1000 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
300 mcg
general disorders and administration site conditions 100% (placebo 62.5%)
muscoloskeletal and connective tissue disorders 66.7% (placebo 25%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40/300 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 50% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
300 mcg
nervous system disorders 100% (placebo 62.5%)
infections and infestations 71.4% (placebo 62.5%)
vascular disorders 42.9% (placebo 0%)
NCT04075318 · Phase 1 · monotherapy
300/100 mcg
injury, poisoning and procedural complications 85.7% (placebo 0%)
nervous system disorders 85.7% (placebo 62.5%)
general disorders and administration site conditions 57.1% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
100 mcg
general disorders and administration site conditions 66.7% (placebo 62.5%)
infections and infestations 66.7% (placebo 62.5%)
nervous system disorders 50% (placebo 62.5%)
NCT04075318 · Phase 1 · monotherapy
40 mcg
general disorders and administration site conditions 83.3% (placebo 62.5%)
nervous system disorders 66.7% (placebo 62.5%)
muscoloskeletal and connective tissue disorders 33.3% (placebo 25%)
NCT04075318 · Phase 1 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY3962681's landscape · UB-312's landscape